Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, October 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 258 articles:
HTML format


 

Single Articles

  1. QIU H, Wang J, Zhi Y, Yan B, et al
    Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer.
    ACS Appl Mater Interfaces. 2023 Sep 28. doi: 10.1021/acsami.3c09564.
    PubMed    
    Abstract available

  2. ZOU F, Chen W, Song T, Xing J, et al
    SQLE Knockdown inhibits bladder cancer progression by regulating the PTEN/AKT/GSK3beta signaling pathway through P53.
    Cancer Cell Int. 2023;23:221.
    PubMed    
    Abstract available

  3. ZHAN Y, Liu Y, Lin J, Fu X, et al
    Author Correction: Synthetic Tet-inducible artificial microRNAs targeting beta-catenin or HIF-1alpha inhibit malignant phenotypes of bladder cancer cells T24 and 5637.
    Sci Rep. 2023;13:16331.
    PubMed    


  4. ZHANG W, Cai K, Sun Z, Xiang Q, et al
    Elevating Second Near-Infrared Photothermal Conversion Efficiency of Hollow Gold Nanorod for a Precise Theranostic of Orthotopic Bladder Cancer.
    ACS Nano. 2023 Sep 28. doi: 10.1021/acsnano.3c04175.
    PubMed    
    Abstract available

  5. YANOVA MR, Zhiyanov AP, Antipenko ID, Slobodov SA, et al
    Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer.
    Dokl Biochem Biophys. 2023 Sep 29. doi: 10.1134/S1607672923700503.
    PubMed    
    Abstract available

  6. PETEINARIS A, Perros P, Prokopakis I, Fasoulakis Z, et al
    Bladder Cancer during Pregnancy: A Review of the Literature.
    J Pers Med. 2023;13:1418.
    PubMed    
    Abstract available

  7. SCHULZ HAGERSTEN E, Ottosson K, Pelander S, Johansson M, et al
    The Risk of Thromboembolism in Patients with Muscle Invasive Bladder Cancer before and after Cystectomy Depending on Blood Group and Neoadjuvant Chemotherapy-A Multicentre Retrospective Cohort Study.
    J Pers Med. 2023;13:1355.
    PubMed    
    Abstract available

  8. YE L, Wang Y, Xiang W, Yao J, et al
    Radiomic Analysis of Quantitative T2 Mapping and Conventional MRI in Predicting Histologic Grade of Bladder Cancer.
    J Clin Med. 2023;12:5900.
    PubMed    
    Abstract available

  9. FLORES MONAR GV, Reynolds T, Gordon M, Moon D, et al
    Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.
    Int J Mol Sci. 2023;24:14374.
    PubMed    
    Abstract available

  10. ELAHI NAJAFI MA, Yasui M, Teramoto Y, Tatenuma T, et al
    GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
    Int J Mol Sci. 2023;24:13733.
    PubMed    
    Abstract available

  11. KHORAMINIA F, Fuster S, Kanwal N, Olislagers M, et al
    Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review.
    Cancers (Basel). 2023;15:4518.
    PubMed    
    Abstract available

  12. ELKARTA A, Awadalla A, El-Hefnawy A, Mosbah A, et al
    Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study.
    Clin Genitourin Cancer. 2023 Aug 10:S1558-7673(23)00186.
    PubMed    
    Abstract available

  13. SACHKO AM, Goryainova OS, Ivanova TI, Nikolaeva IY, et al
    Analysis of Transferrin in the Urine of Patients with Bladder Cancer Using Nanobodies.
    Biochemistry (Mosc). 2023;88:1105-1115.
    PubMed    
    Abstract available

  14. TAN M, Pan Q, Gong H, Zhai X, et al
    Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway.
    Pharmacol Res. 2023 Sep 25:106940. doi: 10.1016/j.phrs.2023.106940.
    PubMed    
    Abstract available

  15. SLUSARCZYK A, Zapala P
    Reply to Letter to Editor: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Sep 27. doi: 10.1245/s10434-023-14360.
    PubMed    


  16. SABATE ORTEGA J, Fort Culillas R, Escoda Garcia M, Vasquez-Dongo CA, et al
    Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.
    Curr Oncol. 2023;30:7802-7809.
    PubMed    
    Abstract available

  17. KOGA F
    Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future.
    Expert Rev Anticancer Ther. 2023 Sep 27:1-13. doi: 10.1080/14737140.2023.2257389
    PubMed    
    Abstract available

  18. ZHENG K, Li M
    Predicting Survival Signature of Bladder Cancer Related to Cancer-Associated Fibroblast (CAF) Constructed by Intersecting Genes in TCGA and GEO.
    Mol Biotechnol. 2023 Sep 25. doi: 10.1007/s12033-023-00892.
    PubMed    
    Abstract available

  19. LIND AK, Liedberg F, Aljabery F, Blackberg M, et al
    Health-related quality of life prior to and 1 year after radical cystectomy evaluated with FACT-G and FACT-VCI questionnaires.
    Scand J Urol. 2023;58:76-83.
    PubMed    
    Abstract available

  20. MAGALHAES JC, Sousa M, Basto R, Fraga T, et al
    Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
    Cureus. 2023;15:e45672.
    PubMed    
    Abstract available

  21. LIANG T, Tao T, Wu K, Liu L, et al
    Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer.
    Adv Sci (Weinh). 2023 Sep 24:e2303230. doi: 10.1002/advs.202303230.
    PubMed    
    Abstract available

  22. WANG L, Song R, Ma M, Chen Y, et al
    Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced by SC66 through the endoplasmic reticulum stress pathway.
    Chem Biol Interact. 2023 Sep 21:110725. doi: 10.1016/j.cbi.2023.110725.
    PubMed    
    Abstract available

  23. LIU J, Wu P, Lai S, Wang J, et al
    Identifying possible hub genes and biological mechanisms shared between bladder cancer and inflammatory bowel disease using machine learning and integrated bioinformatics.
    J Cancer Res Clin Oncol. 2023 Sep 23. doi: 10.1007/s00432-023-05266.
    PubMed    
    Abstract available

  24. LIU T, Fan MQ, Xie XX, Shu QP, et al
    Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression.
    J Transl Med. 2023;21:656.
    PubMed    
    Abstract available

  25. WANG X, Liu J, Azoitei A, Eiseler T, et al
    Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics.
    Cell Mol Life Sci. 2023;80:299.
    PubMed    
    Abstract available

  26. ZOU F, Rao T, Chen W, Song T, et al
    DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7.
    Cell Signal. 2023;112:110893.
    PubMed    
    Abstract available

  27. KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
    MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.
    Diagn Pathol. 2023;18:106.
    PubMed    
    Abstract available

  28. JIANG R, Wang X, Li Z, Cai H, et al
    Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.
    BMC Urol. 2023;23:150.
    PubMed    
    Abstract available

  29. LI W, Li C, Liu T, Wang Y, et al
    Self-reported sleep disorders and the risk of all cancer types: evidence from the Kailuan Cohort study.
    Public Health. 2023;223:209-216.
    PubMed    
    Abstract available

  30. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
    Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1205-1213.
    PubMed    
    Abstract available

  31. GODARD L, Lee L, McGuinness B, Shirsat H, et al
    Mycotic Abdominal Aortic Aneurysm Secondary to BCG Therapy for Non-muscle Invasive Urothelial Carcinoma of the Bladder.
    Vasc Endovascular Surg. 2023;57:776-780.
    PubMed    
    Abstract available

  32. SEKIGUCHI Y, Nishimura Y, Kanda H, Kawamura M, et al
    A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder Cancer.
    Gan To Kagaku Ryoho. 2023;50:985-992.
    PubMed    
    Abstract available

  33. METHODS IN MEDICINE CAM
    Retracted: MicroRNA-143-3p/TBX3 Axis Represses Malignant Cell Behaviors in Bladder Cancer.
    Comput Math Methods Med. 2023;2023:9763968.
    PubMed    
    Abstract available

  34. METHODS IN MEDICINE CAM
    Retracted: The Effect of Narrative Nursing Intervention on Shame in Elderly Patients with Bladder Cancer after Ileal Bladder Replacement: A Cohort Study.
    Comput Math Methods Med. 2023;2023:9761783.
    PubMed    
    Abstract available

  35. KIM Y, Ju H, Yoo SY, Jeong J, et al
    Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer.
    Cell Rep Med. 2023 Sep 27:101224. doi: 10.1016/j.xcrm.2023.101224.
    PubMed    
    Abstract available

  36. HUSSEIN AA, Bhat TA, Jing Z, Gomez EC, et al
    Does the urinary microbiome profile change after treatment of bladder cancer?
    World J Urol. 2023 Oct 5. doi: 10.1007/s00345-023-04627.
    PubMed    
    Abstract available

  37. HATTORI Y, Kato M, Imamura T, Inaba S, et al
    [Idiopathic Thrombocytopenia Purpura After Pembrolizumab Treatment Against Locally Recurrent Bladder Cancer : A Case Report].
    Hinyokika Kiyo. 2023;69:255-258.
    PubMed    
    Abstract available

  38. KIM CJ, Ide H, Nakamura M, Hanada E, et al
    [Occurrence of Distant Metastasis During Bladder Presevation in T1 high-grade Bladder Cancer: Report of Three Cases].
    Hinyokika Kiyo. 2023;69:249-254.
    PubMed    
    Abstract available

  39. LI R
    Organ-sparing precision treatment for muscle-invasive bladder cancer.
    Nat Med. 2023 Oct 4. doi: 10.1038/s41591-023-02575.
    PubMed    


  40. MOREO E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, et al
    Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.
    Nat Commun. 2023;14:6090.
    PubMed    
    Abstract available

  41. VIEIRA HM, Kasper DP, Wang R, Smith LM, et al
    Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer.
    Radiat Oncol J. 2023;41:154-162.
    PubMed    
    Abstract available

  42. XIONG S, Li S, Zeng J, Nie J, et al
    Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Front Immunol. 2023;14:1253586.
    PubMed    
    Abstract available

  43. PAN G, Jiang B, Yi Z, Yin J, et al
    Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer.
    BMC Urol. 2023;23:155.
    PubMed    
    Abstract available

  44. INOUE Y, Yamada T, Fujihara A, Miyashita M, et al
    Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study.
    Sci Rep. 2023;13:16580.
    PubMed    
    Abstract available

  45. OKADA M, Shindo T, Fujino K, Maeda T, et al
    Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.
    Support Care Cancer. 2023;31:607.
    PubMed    
    Abstract available

  46. NORGAARD M, Mailhac A, Fagerlund K, Strunz-McKendry T, et al
    Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2020.
    Acta Oncol. 2023 Oct 3:1-7. doi: 10.1080/0284186X.2023.2263154.
    PubMed    
    Abstract available

  47. WANG M, Zhang C, Ying Y, Hua M, et al
    PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of bladder cancer.
    Mol Carcinog. 2023 Oct 3. doi: 10.1002/mc.23643.
    PubMed    
    Abstract available

  48. ZAIDI N, Siddiqui Z, Sankhwar SN, Srivastava AN, et al
    Urinary microRNA-10a levels in diagnosis and prognosis of urinary bladder cancer.
    J Cancer Res Ther. 2023;19:1324-1329.
    PubMed    
    Abstract available

  49. WU T, Li N, Wu X, Du Y, et al
    LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer.
    Open Med (Wars). 2023;18:20230788.
    PubMed    
    Abstract available

  50. ZHENG J, Lu S, Huang Y, Chen X, et al
    Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.
    J Transl Med. 2023;21:685.
    PubMed    
    Abstract available

  51. GALSKY MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, et al
    Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02568.
    PubMed    
    Abstract available

  52. WANG G, He X, Dai H, Lin L, et al
    WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2.
    Oncogenesis. 2023;12:47.
    PubMed    
    Abstract available

  53. ZUO M, Chen H, Liao Y, He P, et al
    Sulforaphane and bladder cancer: a potential novel antitumor compound.
    Front Pharmacol. 2023;14:1254236.
    PubMed    
    Abstract available

  54. WANG X, Pan J, Guan Q, Ren N, et al
    Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer.
    Front Pharmacol. 2023;14:1215296.
    PubMed    
    Abstract available

  55. FRERICHS LM, Frerichs B, Petzsch P, Kohrer K, et al
    Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells.
    Front Oncol. 2023;13:1228185.
    PubMed    
    Abstract available

  56. WU Z, Feng Z, Wei H, Lin C, et al
    Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer.
    Front Med (Lausanne). 2023;10:1193133.
    PubMed    
    Abstract available

  57. ROSLAN A, Said DS, Sulaiman N, Mohd Ghani KA, et al
    Cluster of differentiation 147 (CD147) as potential membrane protein biomarker for bladder cancer cells.
    J Pharm Biomed Anal. 2023;236:115729.
    PubMed    
    Abstract available

  58. XU JH, Shao GZ, Yang YF, Fan ZQ, et al
    Comment on: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Sep 30. doi: 10.1245/s10434-023-14355.
    PubMed    


  59. YAN H, Zhang L, Li R
    Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and immunotherapy biomarker through bladder cancer clinical data validation and pan-cancer analysis.
    Sci Rep. 2023;13:16457.
    PubMed    
    Abstract available

  60. SONG Y, Peng Y, Qin C, Wang Y, et al
    Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    J Immunother Cancer. 2023;11:e006643.
    PubMed    
    Abstract available

  61. BUDAYA TN, Permatasari HK, Widodo N, Prawiro SR, et al
    The Evolution of Polyclonal Antibody from Specific Epitope 47kDA for Detection of Bladder Cancer.
    Asian Pac J Cancer Prev. 2023;24:3155-3164.
    PubMed    
    Abstract available

  62. ASGARI M, Firouzi F, Abolhasani M, Bahadoram M, et al
    The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder.
    Asian Pac J Cancer Prev. 2023;24:3125-3131.
    PubMed    
    Abstract available

  63. CHALHOUB IG, Boulos RT, Dagher YG, El Helou S, et al
    Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study.
    Medicine (Baltimore). 2023;102:e34562.
    PubMed    
    Abstract available

  64. TORON M, Woloszyn A
    [Organ-sparing treatment of node-positive bladder cancer].
    Strahlenther Onkol. 2023 Sep 29. doi: 10.1007/s00066-023-02156.
    PubMed    


  65. YANG J, Tan Y, Yao C
    Study on anxiety, depression, and subjective wellbeing of patients with bladder cancer in their different chemotherapy stages.
    Front Psychol. 2023;14:1226712.
    PubMed    
    Abstract available

  66. LIU Y, Pang ZQ, Wang JS, Wang JF, et al
    Heat shock protein family A member 8 is a prognostic marker for bladder cancer: Evidences based on experiments and machine learning.
    J Cell Mol Med. 2023 Sep 28. doi: 10.1111/jcmm.17977.
    PubMed    
    Abstract available

  67. ZHANG X, Hu X, Xie Y, Xie L, et al
    Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration.
    Molecules. 2023;28:6720.
    PubMed    
    Abstract available

  68. YOO D, Min KW, Pyo JS, Kim NY, et al
    Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ.
    Medicina (Kaunas). 2023;59:1609.
    PubMed    
    Abstract available

  69. LU XJ, Lai HF, Wu SC, Chen CL, et al
    Elucidating the Associated Biological Function and Clinical Significance of RHOJ Expression in Urothelial Carcinoma.
    Int J Mol Sci. 2023;24:14081.
    PubMed    
    Abstract available

  70. NAKAMURA M, Tsuru I, Izumi T, Ono A, et al
    Advantages of enhanced recovery after surgery program in robot-assisted radical cystectomy.
    Sci Rep. 2023;13:16237.
    PubMed    
    Abstract available

  71. GAMBA T, Paparo J, Panepinto O, Dionisio R, et al
    Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
    Clin Genitourin Cancer. 2023;21:509-516.
    PubMed    
    Abstract available

  72. NISHIYAMA H, Tsuzuki T, Ohyama C, Matsuyama H, et al
    Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
    Int J Clin Oncol. 2023;28:1398-1410.
    PubMed    
    Abstract available

  73. BETTOLI P, Liu Z, Jara N, Bakal F, et al
    Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network.
    Arch Ital Urol Androl. 2023;95:11533.
    PubMed    
    Abstract available

  74. RAO N, Starrett GJ, Piaskowski ML, Butler KE, et al
    Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
    Cancer Prev Res (Phila). 2023;16:561-570.
    PubMed    
    Abstract available

  75. MANCIULLI T, Marangoni D, Salas-Coronas J, Bocanegra C, et al
    Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature.
    Infection. 2023;51:1185-1221.
    PubMed    
    Abstract available

  76. COTE G, Alqaisi H, Chan CT, Jiang DM, et al
    Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma.
    Kidney360. 2023;4:e1203-e1211.
    PubMed    
    Abstract available

  77. KONDO Y, Nagamine Y, Yoshikawa N, Echigo N, et al
    Incidence of perioperative hypotension in patients undergoing transurethral resection of bladder tumor after oral 5-aminolevulinic acid administration: a retrospective multicenter cohort study.
    J Anesth. 2023;37:703-713.
    PubMed    
    Abstract available

  78. FERRO M, Crocetto F, Tataru S, Barone B, et al
    Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2023;21:574-583.
    PubMed    
    Abstract available

  79. BAKALOUDI DR, Talukder R, Lin GI, Makrakis D, et al
    Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Clin Genitourin Cancer. 2023;21:584-593.
    PubMed    
    Abstract available

  80. LEVY JJ, Chan N, Marotti JD, Kerr DA, et al
    Large-scale validation study of an improved semiautonomous urine cytology assessment tool: AutoParis-X.
    Cancer Cytopathol. 2023;131:637-654.
    PubMed    
    Abstract available

  81. ZHONG W, Xia K, Liu L, Cheng S, et al
    Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
    Int J Surg. 2023;109:2742-2750.
    PubMed    
    Abstract available

  82. JINDAL T, Zhang L, Deshmukh P, Reyes K, et al
    Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
    Clin Genitourin Cancer. 2023;21:e394-e404.
    PubMed    
    Abstract available

  83. GREENLAND NY, Khorsandi N, Peng Y, Balassanian R, et al
    Utility and performance of cell blocks in urine cytology: Experience at three teaching hospitals.
    Cancer Cytopathol. 2023;131:614-625.
    PubMed    
    Abstract available

  84. PEAK T, Spiess PE, Li R, Grivas P, et al
    Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry.
    Oncologist. 2023;28:e910-e920.
    PubMed    
    Abstract available

  85. PIERANTONI F, Dionese M, Basso U, Lai E, et al
    The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2023;21:e378-e385.
    PubMed    
    Abstract available

  86. DANESHPAJOUHNEJAD P, Morrison C, Zhao X, Daniel RE, et al
    Primary Alveolar Soft-Part Sarcoma (ASPS) of the Prostate: Report of a Deceptive Case.
    Int J Surg Pathol. 2023;31:1359-1363.
    PubMed    
    Abstract available

  87. STOCKLE M
    [Cystectomy versus trimodal therapy for bladder cancer].
    Urologie. 2023 Oct 12. doi: 10.1007/s00120-023-02195.
    PubMed    


  88. LIU K, Zhao H, Chen X, Nicoletti R, et al
    A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guerin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Oct 10:S2588-9311(23)00206.
    PubMed    
    Abstract available

  89. HONG Y, Li Z, Su Y, Pu H, et al
    The ceRNA Mechanism of lncRNA MEG3/miR-21-5p/SPRY2 in Cell Proliferation and Apoptosis in Bladder Cancer.
    Crit Rev Eukaryot Gene Expr. 2024;34:55-68.
    PubMed    
    Abstract available

  90. HONG X, Chen X, Wang H, Xu Q, et al
    A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
    Adv Sci (Weinh). 2023 Oct 12:e2302377. doi: 10.1002/advs.202302377.
    PubMed    
    Abstract available

  91. VAN STRATEN CGJI, Caris C, Grimm MO, Colombel M, et al
    Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guerin Instillations: The EAU-RF NIMBUS Trial.
    Eur Urol Open Sci. 2023;56:15-24.
    PubMed    
    Abstract available

  92. ZHOU YX, Hu QC, Zhu YJ, Mu XL, et al
    Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Eur J Med Res. 2023;28:422.
    PubMed    
    Abstract available

  93. KONG L, Wen Z, Cai Q, Lin Y, et al
    Amide Proton Transfer-Weighted MRI and Diffusion-Weighted Imaging in Bladder Cancer: A Complementary Tool to the VI-RADS.
    Acad Radiol. 2023 Oct 9:S1076-6332(23)00472-5. doi: 10.1016/j.acra.2023.
    PubMed    
    Abstract available

  94. LI R, Jiang B, Zhu Y, Gao L, et al
    Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report.
    Endocr Metab Immune Disord Drug Targets. 2023.
    PubMed    
    Abstract available

  95. JENA R, Bhargava P, Tripathi S, Taywade S, et al
    18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.
    BJUI Compass. 2023;4:662-667.
    PubMed    
    Abstract available

  96. AN H, Liu K, Shirai K, Kawasaki R, et al
    Physical Activity and Bladder Cancer Risk: Findings of the Japan Collaborative Cohort Study.
    Cancer Res Treat. 2023 Oct 6. doi: 10.4143/crt.2023.
    PubMed    
    Abstract available

  97. ZHENG Y, Shi D, Chen L, Yang Y, et al
    UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  98. ZHANG X, Wu H, Wang S
    [SLC12A8 promotes proliferation, invasiveness, migration and epithelial-mesenchymal transition of bladder cancer cells by activating JAK/STAT singaling].
    Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1613-1621.
    PubMed    
    Abstract available

  99. ZHOU Q, Huang W, Xiong J, Guo B, et al
    CDCA8 promotes bladder cancer survival by stabilizing HIF1alpha expression under hypoxia.
    Cell Death Dis. 2023;14:658.
    PubMed    
    Abstract available

  100. ECKSTEIN M, Matek C, Wagner P, Erber R, et al
    Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].
    Eur Urol Oncol. 2023 Oct 7:S2588-9311(23)00215-8. doi: 10.1016/j.euo.2023.
    PubMed    


  101. TAARNHOJ GA, Johansen C, Carus A, Dahlrot RH, et al
    The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial.
    J Patient Rep Outcomes. 2023;7:99.
    PubMed    
    Abstract available

  102. FRESHOUR SL, Chen TH, Fisk B, Shen H, et al
    Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.
    iScience. 2023;26:107937.
    PubMed    
    Abstract available

  103. ZHANG Y, Xu Z, Wu S, Zhu T, et al
    Construction of 3D and 2D contrast-enhanced CT radiomics for prediction of CGB3 expression level and clinical prognosis in bladder cancer.
    Heliyon. 2023;9:e20335.
    PubMed    
    Abstract available

  104. HUANG L, Xie Q, Deng J, Wei WF, et al
    The role of cancer-associated fibroblasts in bladder cancer progression.
    Heliyon. 2023;9:e19802.
    PubMed    
    Abstract available

  105. LIU HR, Peng X, Li SL, Gou X, et al
    [Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2023;55:793-801.
    PubMed    
    Abstract available

  106. WEICKHARDT A, Foroudi F, Lawrentschuk N, Xie J, et al
    Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
    Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00201-8. doi: 10.1016/j.euo.2023.
    PubMed    
    Abstract available

  107. CONTIERI R, Hensley PJ, Kamat AM
    Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscl
    Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00210-9. doi: 10.1016/j.euo.2023.
    PubMed    


  108. YANG Y, Miao L, Lu Y, Sun Y, et al
    Exosome, the glass slipper for Cinderella of cancer-bladder cancer?
    J Nanobiotechnology. 2023;21:368.
    PubMed    
    Abstract available

  109. HUANG WB, Cheng L
    [Research progress in molecular pathology of bladder cancer].
    Zhonghua Bing Li Xue Za Zhi. 2023;52:1074-1078.
    PubMed    


  110. MOSSANEN M, Smith AB, Onochie N, Matulewicz R, et al
    Bladder cancer patient and provider perspectives on smoking cessation.
    Urol Oncol. 2023 Oct 5:S1078-1439(23)00292-2. doi: 10.1016/j.urolonc.2023.
    PubMed    
    Abstract available

  111. VALDEZ-FLORES C, Erraguntla N, Budinsky R, Cagen S, et al
    Corrigendum to "An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene" [Chem. Biol. Interact. 366 (2022) 1-10].
    Chem Biol Interact. 2023;385:110736.
    PubMed    


  112. FAN ZC, Zhang L, Yang GQ, Li S, et al
    MRI radiomics for predicting poor disease-free survival in muscle invasive bladder cancer: the results of the retrospective cohort study.
    Abdom Radiol (NY). 2023 Oct 7. doi: 10.1007/s00261-023-04028.
    PubMed    
    Abstract available

  113. AZZAROUALI S, Goudschaal K, Visser J, Hulshof M, et al
    Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers.
    Radiat Oncol. 2023;18:165.
    PubMed    
    Abstract available

  114. YU A, Hu J, Fu L, Huang G, et al
    Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition.
    J Immunother Cancer. 2023;11:e007230.
    PubMed    
    Abstract available

  115. CHEN J, Li H, Wu Y, Li Y, et al
    Shared genetic links between bladder cancer and obesity-related traits: A conjunctional false discovery rate study.
    Medicine (Baltimore). 2023;102:e35145.
    PubMed    
    Abstract available

  116. VAN ZUTPHEN M, Beeren I, Aben KKH, van der Heijden AG, et al
    Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer.
    Cancer Med. 2023 Oct 6. doi: 10.1002/cam4.6620.
    PubMed    
    Abstract available

  117. BELSEY J
    A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix(R) in patients diagnosed with non-muscle-invasive bladder cancer in France.
    J Med Econ. 2023 Oct 6:1-10. doi: 10.1080/13696998.2023.2267929.
    PubMed    
    Abstract available

  118. LI WM, Chan TC, Wei YC, Li CF, et al
    Downregulation of CRTAC1 in Urothelial Carcinoma Promotes Tumor Aggressiveness and Confers Poor Prognosis.
    Front Biosci (Landmark Ed). 2023;28:217.
    PubMed    
    Abstract available

  119. TONG G, Wang X, Chen S, Jin Y, et al
    Astragalus polysaccharide inhibits the development of urothelial carcinoma by activating AMPK signaling to induce BENC1-xCT complex formation.
    Aging (Albany NY). 2023;15:9438-9452.
    PubMed    
    Abstract available

  120. ROCH C, Para S, Brandhofer C, Seitz AK, et al
    Successful use of Rectal Pregabalin for the Treatment of Chemotherapy-Induced Neuropathic Pain-a Case Report.
    J Palliat Care. 2023;38:412-415.
    PubMed    
    Abstract available

  121. DAYCO JS, DeSouza N, Cardozo S
    A cluster of grapes: Right atrial masses of uncertain origin.
    J Vasc Access. 2023;24:821-823.
    PubMed    
    Abstract available

  122. ZENG T, Ye J, Wang H, Tian W, et al
    Identification of pyroptosis-related lncRNA subtype and signature predicts the prognosis in bladder cancer.
    Medicine (Baltimore). 2023;102:e35195.
    PubMed    
    Abstract available

  123. HEALTHCARE ENGINEERING JO
    Retracted: Multi-Slice Spiral Computed Tomography Image Features under Hybrid Iterative Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.
    J Healthc Eng. 2023;2023:9791241.
    PubMed    
    Abstract available

  124. LI H, Long G, Tian J
    Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2023;13:1255632.
    PubMed    
    Abstract available

  125. OZDEMIR H, Azamat S, Sam Ozdemir M
    Can Only the Shape Feature in Radiomics Help Machine Learning Show That Bladder Cancer Has Invaded Muscles?
    Cureus. 2023;15:e45488.
    PubMed    
    Abstract available

  126. YUAN F, Sun Y, Dai GC, Yao Q, et al
    Comprehensive Analysis of Prognostic Value and Immune Infiltration of TFAP2 Family Members in Bladder Cancer from Database and FFPE Sample.
    J Cancer. 2023;14:3050-3065.
    PubMed    
    Abstract available

  127. KHETRAPAL P, Bains PS, Jubber I, Ambler G, et al
    Digital Tracking of Patients Undergoing Radical Cystectomy for Bladder Cancer: Daily Step Counts Before and After Surgery Within the iROC Randomised Controlled Trial.
    Eur Urol Oncol. 2023 Oct 16:S2588-9311(23)00213.
    PubMed    
    Abstract available

  128. DURANT AM, Choudry MM, Madura G, Mi L, et al
    Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
    Urol Oncol. 2023 Oct 16:S1078-1439(23)00323.
    PubMed    
    Abstract available

  129. SHEN C, Han C, Li Z, Yan Y, et al
    Construction and Validation of a Prognostic Model Based on Pyroptosisrelated Genes in Bladder Cancer.
    Comb Chem High Throughput Screen. 2023.
    PubMed    
    Abstract available

  130. WANG W, Yang F, Zhang L, Wang M, et al
    Targeting Dna Damage and Repair Machinery via Delivering WEE1 Inhibitor and Platinum (IV) Prodrugs to Stimulate Sting Pathway for Maximizing Chemo-immunotherapy in Bladder Cancer.
    Adv Mater. 2023 Oct 17:e2308762. doi: 10.1002/adma.202308762.
    PubMed    
    Abstract available

  131. ZHOU J, Dong C, Tan J, Wang G, et al
    Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-kappaB pathways.
    Apoptosis. 2023 Oct 17. doi: 10.1007/s10495-023-01898.
    PubMed    
    Abstract available

  132. KANG KA, Kim MJ, Kwon GY, Kim CK, et al
    Computed tomography-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer.
    Abdom Radiol (NY). 2023 Oct 17. doi: 10.1007/s00261-023-04069.
    PubMed    
    Abstract available

  133. BRYAN RT, Pirrie SJ, Abbotts B, Maycock S, et al
    Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.
    JAMA Netw Open. 2023;6:e2337494.
    PubMed    
    Abstract available

  134. ZOU Z, Li Z, Sun W, Gao W, et al
    Establishment of prognostic model of bladder cancer based on apoptosis-related genes, in which P4HB promotes BLCA progression.
    BMC Urol. 2023;23:167.
    PubMed    
    Abstract available

  135. ZHU CZ, Ting HN, Ng KH, Mun KS, et al
    Dielectric properties of urine in relation to bladder cancer.
    Phys Eng Sci Med. 2023 Oct 16. doi: 10.1007/s13246-023-01341.
    PubMed    
    Abstract available

  136. ABOU CHAKRA M, Packiam VT, O'Donnell MA
    Real-word efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer.
    Expert Opin Pharmacother. 2023 Oct 16:1-11. doi: 10.1080/14656566.2023.2271396.
    PubMed    
    Abstract available

  137. LIATSOS GD, Manousopoulou G, Poulaki A, Iliaki A, et al
    Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure.
    Access Microbiol. 2023;5:000670.
    PubMed    
    Abstract available

  138. NGUYEN TT, Thanh HD, Do MH, Jung C, et al
    Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the Migration of Bladder Cancer Cells.
    Chonnam Med J. 2023;59:160-166.
    PubMed    
    Abstract available

  139. PRINCE MR, Shaish H
    Editorial for "Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System".
    J Magn Reson Imaging. 2023 Oct 15. doi: 10.1002/jmri.29054.
    PubMed    


  140. CARAPITO A, Roque ACA, Carvalho F, Pinto J, et al
    Exploiting volatile fingerprints for bladder cancer diagnosis: A scoping review of metabolomics and sensor-based approaches.
    Talanta. 2023;268.
    PubMed    
    Abstract available

  141. AVUDAIAPPAN AP, Prabhakar P, Ganapathi H, VanderVeer-Harris N, et al
    Propensity score matched survival analysis of octogenarians with muscle-invasive bladder cancer: chemoradiation compared to radical cystectomy.
    Can J Urol. 2023;30:11686-11691.
    PubMed    
    Abstract available

  142. MONTORSI F, Rosiello G, Gandaglia G
    Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy.
    Eur Urol Oncol. 2023 Oct 12:S2588-9311(23)00208.
    PubMed    


  143. DI GIANFRANCESCO L, Crestani A, Amodeo A, Corsi P, et al
    The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from Bladder Cancer: A Narrative Review.
    Diagnostics (Basel). 2023;13:3119.
    PubMed    
    Abstract available

  144. LEE J, Yoo S, Choo MS, Cho MC, et al
    Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and Recurrence at First Evaluation after Bacillus Calmette-Guerin (BCG) Induction in Non-Muscle-Invasive Bladder Cancer.
    Diagnostics (Basel). 2023;13:3114.
    PubMed    
    Abstract available

  145. MORI K, Matsumoto K, Ikeda M, Koguchi D, et al
    Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.
    Diagnostics (Basel). 2023;13:3067.
    PubMed    
    Abstract available

  146. JUENGEL E, Rutz J, Meiborg M, Markowitsch SD, et al
    Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation.
    Cancers (Basel). 2023;15:4849.
    PubMed    
    Abstract available

  147. LIOSIS KC, Marouf AA, Rokne JG, Ghosh S, et al
    Genomic Biomarker Discovery in Disease Progression and Therapy Response in Bladder Cancer Utilizing Machine Learning.
    Cancers (Basel). 2023;15:4801.
    PubMed    
    Abstract available

  148. COURBOIN E, Mathieu R, Panetta V, Mjaess G, et al
    Comparing Robotic-Assisted to Open Radical Cystectomy in the Management of Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched-Pair Analysis.
    Cancers (Basel). 2023;15:4732.
    PubMed    
    Abstract available

  149. DAVALIEVA K, Kiprijanovska S, Ivanovski O, Trifunovski A, et al
    Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
    Int J Mol Sci. 2023;24:14938.
    PubMed    
    Abstract available

  150. KATSUMATA H, Matsumoto K, Yanagita K, Shimizu Y, et al
    Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy.
    Int J Mol Sci. 2023;24:14536.
    PubMed    
    Abstract available

  151. LUO J, Guo L, Chen L, Zhou J, et al
    Efficacy and safety of HIVEC versus ETFT in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Asian J Surg. 2023 Oct 11:S1015-9584(23)01573.
    PubMed    


  152. LI H, Lv Z, Liu M
    A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors.
    Medicine (Baltimore). 2023;102:e35196.
    PubMed    
    Abstract available

  153. GOZUKUCUK R, Cakiroglu B
    [Miliary Pulmonary Tuberculosis After Intravesical BCG Instillation in a Patient with High-Grade Bladder Cancer].
    Mikrobiyol Bul. 2023;57:675-681.
    PubMed    
    Abstract available

  154. HAM WS, Park JS, Jang WS, Kim J, et al
    Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Oct 26. doi: 10.1245/s10434-023-14449.
    PubMed    
    Abstract available


  155. Bladder cancer.
    Nat Rev Dis Primers. 2023;9:59.
    PubMed    


  156. DYRSKJOT L, Hansel DE, Efstathiou JA, Knowles MA, et al
    Bladder cancer.
    Nat Rev Dis Primers. 2023;9:58.
    PubMed    
    Abstract available

  157. TAN X, Liu Z, Cai T, Wang Y, et al
    Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Oct 24:S2588-9311(23)00219.
    PubMed    
    Abstract available

  158. SRETENOVIC M, Bojanic N, Grozdic Milojevic I, Bumbasirevic U, et al
    Diagnostic and prognostic impact of preoperative thrombocytosis in muscle invasive bladder cancer: Any role in clinical practice?
    J Clin Ultrasound. 2023 Oct 26. doi: 10.1002/jcu.23600.
    PubMed    
    Abstract available

  159. LUO Z, Yan Y, Jiao B, Huang T, et al
    Prognostic value of the systemic immune-inflammation index in patients with upper tract urothelial carcinoma after radical nephroureterectomy.
    World J Surg Oncol. 2023;21:337.
    PubMed    
    Abstract available

  160. SHEN C, Bi Y, Chai W, Zhang Z, et al
    Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
    BMC Med Genomics. 2023;16:264.
    PubMed    
    Abstract available

  161. FAROUK SM, Khafaga AF, Abdellatif AM
    Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics.
    Cancer Cell Int. 2023;23:251.
    PubMed    
    Abstract available

  162. LI R, Naidu S, Fan W, Rose K, et al
    Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
    Urol Oncol. 2023 Oct 23:S1078-1439(23)00332.
    PubMed    
    Abstract available

  163. UCHIDA Y, Yokoyama M, Fujiwara M, Nakamura Y, et al
    Preservation of Erectile and Ejaculatory Functions After Tetramodal Bladder-Sparing Therapy Incorporating Consolidative Partial Cystectomy Against Muscle Invasive Bladder Cancer.
    Urol Res Pract. 2023;49:162-168.
    PubMed    
    Abstract available

  164. ALKANLI N, Ay A
    Investigation of the Roles of MTHFR (C677T and A1298C) and MMP-2 (-1306C>T ) Variations in Bladder Cancer Development.
    Urol Res Pract. 2023;49:33-39.
    PubMed    
    Abstract available

  165. EFILOGLU O, Cakici MC, Kir G, Iplikci A, et al
    The Impact of Histological Variants on Oncological Outcomes in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy.
    Urol Res Pract. 2023;49:246-252.
    PubMed    
    Abstract available

  166. BERKOVA A, Chovanec Z, Krejcova I, Katolicka J, et al
    A rare case of urothelial carcinoma metastasizing to the gallbladder wall with manifestations as acute cholecystitis.
    Klin Onkol. 2023;36:401-404.
    PubMed    
    Abstract available

  167. KHAN SM, Das T, Chakraborty S, Choudhury AMAR, et al
    A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.
    Heliyon. 2023;9:e21058.
    PubMed    
    Abstract available

  168. HAO L, Mu D, Mu H
    Sakuranin represses the malignant biological behaviors of human bladder cancer cells by triggering autophagy via activating the p53/mTOR pathway.
    BMC Urol. 2023;23:170.
    PubMed    
    Abstract available

  169. WEI Y, Yang X, Zhu H, Zhuang J, et al
    Impact of the COVID-19 pandemic on bladder cancer patients: a multicenter real-world study.
    J Int Med Res. 2023;51:3000605231204465.
    PubMed    
    Abstract available

  170. CATTO JWF, Tran B, Roupret M, Gschwend JE, et al
    Erdafitinib in BCG-treated high-risk non-muscle invasive bladder cancer.
    Ann Oncol. 2023 Oct 5:S0923-7534(23)04015-2. doi: 10.1016/j.annonc.2023.09.3116.
    PubMed    
    Abstract available

  171. LI B, Li X, Li Z, Yang P, et al
    Magnetic resonance radiographic features which might lead to misdiagnosis of muscle-invasive bladder cancer based on vesical imaging reporting and data system: the application experience of a single center.
    Quant Imaging Med Surg. 2023;13:7258-7268.
    PubMed    
    Abstract available

  172. WARLI SM, Prapiska FF, Siregar DIS, Seja IA, et al
    Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy.
    World J Oncol. 2023;14:423-429.
    PubMed    
    Abstract available

  173. KIM HJ, Kim KH, Lee SW, Swan H, et al
    Familial Risk and Interaction With Smoking and Alcohol Consumption in Bladder Cancer: A Population-Based Cohort Study.
    World J Oncol. 2023;14:382-391.
    PubMed    
    Abstract available

  174. ZHANG X, Huang W, Huang T, Zhang J, et al
    Integrative analysis of triphenyl phosphate: contextual interpretation of bladder cancer cohort.
    Front Oncol. 2023;13:1260114.
    PubMed    
    Abstract available

  175. ZHANG Z, Wang Y, Liang Z, Meng Z, et al
    Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression.
    iScience. 2023;26:108142.
    PubMed    
    Abstract available

  176. WENG M, Deng Z, Huang S, Lin X, et al
    Fraxetin inhibits proliferation and induces apoptosis of bladder cancer through the Akt pathway in vitro and in vivo.
    J Biochem Mol Toxicol. 2023 Oct 23:e23556. doi: 10.1002/jbt.23556.
    PubMed    
    Abstract available

  177. ZHANG X, Liu Q
    Systemic Immune Inflammation Index and T-Staging Predict Prognosis in Patients with Muscle-Invasive Bladder Cancer.
    Arch Esp Urol. 2023;76:511-518.
    PubMed    
    Abstract available

  178. XIA Y, Xiang L, Yao M, Ai Z, et al
    Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and Triggering Ferroptosis.
    Mol Cell Proteomics. 2023 Oct 20:100672. doi: 10.1016/j.mcpro.2023.100672.
    PubMed    
    Abstract available

  179. WANG X, Juncker-Jensen A, Huang G, Nagy ML, et al
    Spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in bladder cancer and prognostic potential for anti-PD-L1 immunotherapy.
    Cancer Commun (Lond). 2023 Oct 20. doi: 10.1002/cac2.12491.
    PubMed    


  180. WU J, Guo Q, Li J, Yuan H, et al
    Loperamide induces protective autophagy and apoptosis through the ROS/JNK signaling pathway in bladder cancer.
    Biochem Pharmacol. 2023;218:115870.
    PubMed    
    Abstract available

  181. WANG Z, Wei B, Ma S
    EGR1/LINC00839/SOX5 axis modulates migration, invasion and Gemcitabine resistance of bladder cancer cells.
    Cancer Biol Ther. 2023;24:2270106.
    PubMed    
    Abstract available

  182. KURBANOV AA, Kryukov SR, Chernov DV, Votyakov AY, et al
    [Robot-assisted left-side partial nephrectomy with a segmental resection of left lower ureter and Boari reconstruction].
    Urologiia. 2023;:125-128.
    PubMed    
    Abstract available

  183. KOLPACINIDI FG, Sergeev VP, Kyzlasov PS, Volokitin EV, et al
    [Experience of using Experience of using NefroBest-N for rehabilitation of patients undergoing radical laparoscopic cystectomy].
    Urologiia. 2023;:62-68.
    PubMed    
    Abstract available

  184. DAMIEV AD, Shpot EV, Akopyan GN, Dymov AM, et al
    [Carboxycryobiopsy and carboxycryoextraction of bladder tumor. Experimental study].
    Urologiia. 2023;:24-29.
    PubMed    
    Abstract available

  185. HERRMANN TRW
    En bloc resection of bladder tumors (ERBT) revisited 12 years after reintroduction: too good to be further ignored.
    World J Urol. 2023;41:2577-2582.
    PubMed    
    Abstract available

  186. MAISCH P, Hwang EC, Kim K, Narayan VM, et al
    Immunotherapy for advanced or metastatic urothelial carcinoma.
    Cochrane Database Syst Rev. 2023;10:CD013774.
    PubMed    
    Abstract available

  187. GOTFREDSEN K, Jandorf S, Zangenberg M, Faber C, et al
    [Not Available].
    Ugeskr Laeger. 2023;185:V04230244.
    PubMed    
    Abstract available

  188. WAN S, Li KP, Wang CY, Chen SY, et al
    Exploring potential targets of HPV&BC based on network pharmacology and urine proteomics.
    J Pharm Biomed Anal. 2023;236:115694.
    PubMed    
    Abstract available

  189. FIALA O, Buti S, Takeshita H, Okada Y, et al
    Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
    Cancer Immunol Immunother. 2023;72:3665-3682.
    PubMed    
    Abstract available

  190. GALLIOLI A, Basile G, Territo A, Verri P, et al
    The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma.
    World J Urol. 2023;41:2743-2749.
    PubMed    
    Abstract available

  191. WHITE RE, Linscott JA, Hayn MT, Ryan ST, et al
    Distance to Treatment With Radical Cystectomy in a Rural State: Long Car Rides, Equivalent Outcomes.
    Urol Pract. 2023;10:588-594.
    PubMed    
    Abstract available

  192. SU PJ, Xiao Y, Lin AY, Goh C, et al
    A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
    Cancer Rep (Hoboken). 2023;6:e1887.
    PubMed    
    Abstract available

  193. QIU J, Deng R, Yu C, Gong K, et al
    The long-term outcome of nephron-sparing surgery versus radical nephroureterectomy for organ-localized upper urinary tract urothelial carcinoma: a population-based study of 1969 patients.
    J Cancer Res Clin Oncol. 2023;149:14869-14878.
    PubMed    
    Abstract available

  194. TEOH JY, D'Andrea D, Gallioli A, Yanagisawa T, et al
    En bloc resection of bladder tumour: the rebirth of past through reminiscence.
    World J Urol. 2023;41:2599-2606.
    PubMed    
    Abstract available

  195. CHEN YT, Yeh HC, Lee HY, Hsieh PF, et al
    Endoscopic management of upper tract urothelial cancer in a highly endemic area: A Taiwan nationwide collaborative study.
    Asian J Surg. 2023;46:3058-3065.
    PubMed    
    Abstract available

  196. BANDARA NA, Zhou XR, Alhamam A, Black PC, et al
    The genitourinary impacts of electronic cigarette use: a systematic review of the literature.
    World J Urol. 2023;41:2637-2646.
    PubMed    
    Abstract available

  197. SONG Y, Peng Y, Xu T
    Letter to the editor for the article "Molecular urothelial tumor cell subtypes remain stable during metastatic evolution".
    World J Urol. 2023;41:2869-2870.
    PubMed    


  198. YANG K, Yu W, Liu H, Lou F, et al
    Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma.
    Cancer Med. 2023;12:15304-15316.
    PubMed    
    Abstract available

  199. LIU J, Lai S, Wu P, Wang J, et al
    Impact of a novel immune and nutritional score on prognosis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy.
    J Cancer Res Clin Oncol. 2023;149:10893-10909.
    PubMed    
    Abstract available

  200. DOUGLAWI A, Ghoreifi A, Carbonara U, Yip W, et al
    Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial Carcinoma: Results From the ROBUUST Collaborative Group.
    Clin Genitourin Cancer. 2023;21:563-568.
    PubMed    
    Abstract available

  201. ENIKEEV D, Morozov A, Shpikina A, Fajkovic H, et al
    A 10-year renaissance of en bloc resection of bladder tumors (ERBT): Are we approaching the peak or is it back to the trough?
    World J Urol. 2023;41:2607-2615.
    PubMed    
    Abstract available

  202. KOBAYASHI Y, Arai H, Hamamoto Y, Yoshida K, et al
    High Infiltration of CD163-Positive Macrophages in Intratumor Compartment Predicts Poor Prognosis in Patients With Upper Urinary Tract Urothelial Carcinoma and Radical Nephroureterectomy.
    Clin Genitourin Cancer. 2023;21:e386-e393.
    PubMed    
    Abstract available

  203. MORALES-BARRERA R, Villacampa G, Vidal N, Figols M, et al
    Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
    Clin Transl Oncol. 2023;25:3556-3564.
    PubMed    
    Abstract available

  204. WANG X, Wang Y, Che X, Zhou Z, et al
    The prognosis and safety of continuous saline bladder irrigation in patients after transurethral resection of bladder tumors: a systematic review and meta-analysis of comparative study.
    Updates Surg. 2023;75:1795-1806.
    PubMed    
    Abstract available

  205. NAGASAKI N, Watanabe T, Edamura K, Araki M, et al
    Bladder Tumors with Multiple Cardiac Metastases, with Elevated Serum Granulocyte Colony-Stimulating Factor.
    Am J Med. 2023;136:e161-e162.
    PubMed    


  206. LAZO JF, Rosa B, Catellani M, Fontana M, et al
    Semi-Supervised Bladder Tissue Classification in Multi-Domain Endoscopic Images.
    IEEE Trans Biomed Eng. 2023;70:2822-2833.
    PubMed    
    Abstract available

  207. CHEIKHROUHOU T, Ben Dhaou M, Charfi S, Hbaieb M, et al
    Phyllodes Tumor of the Bladder in a 2-Year-Old Boy - An Exceptional Finding.
    Fetal Pediatr Pathol. 2023;42:699-705.
    PubMed    
    Abstract available

  208. MATSUZAWA ADACHI M, Sugawara H, Ishii A, Chiba E, et al
    Malignancy-related Hypercalcemia Caused by Metameric Cutaneous Metastasis of Parathyroid Hormone-related Protein-producing Bladder Carcinoma with Squamous Cell Differentiation: An Autopsy Case of Cobb Syndrome.
    Intern Med. 2023 Mar 1. doi: 10.2169/internalmedicine.0893.
    PubMed    
    Abstract available

  209. BREDA A, Gallioli A, Diana P, Fontana M, et al
    The DEpth of Endoscopic Perforation scale to assess intraoperative perforations during transurethral resection of bladder tumor: subgroup analysis of a randomized controlled trial.
    World J Urol. 2023;41:2583-2589.
    PubMed    
    Abstract available

  210. DIANA P, Gallioli A, Fontana M, Territo A, et al
    Energy source comparison in en-bloc resection of bladder tumors: subanalysis of a single-center prospective randomized study.
    World J Urol. 2023;41:2591-2597.
    PubMed    
    Abstract available

  211. GUVEN S, Colecchia M, Oltulu P, Bonfante G, et al
    How do endoscopic bladder tumor resection techniques affect pathology practice? EAU Section of Uro-Technology (ESUT) and Uropathology (ESUP) survey.
    World J Urol. 2023;41:2617-2625.
    PubMed    
    Abstract available

  212. SOMMER U, Grosser M, Aust D, Joehrens K, et al
    PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
    Anticancer Res. 2023;43:4365-4371.
    PubMed    
    Abstract available

  213. NECCHI A, Basile G, Gibb EA, Raggi D, et al
    VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
    PubMed    
    Abstract available

  214. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
    Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
    PubMed    


  215. OUYANG Y, Ou Z, Zhong W, Yang J, et al
    FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation.
    Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065.
    PubMed    
    Abstract available

  216. LI R, Sexton WJ, Dhillon J, Berglund A, et al
    A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
    Clin Cancer Res. 2023;29:3875-3881.
    PubMed    
    Abstract available

  217. KAMRAN SC, Zhou Y, Otani K, Drumm M, et al
    Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0792.
    PubMed    
    Abstract available

  218. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    PubMed    
    Abstract available

  219. CANCEL-TASSIN G, Koutros S
    Use of genomic markers to improve epidemiologic and clinical research in urology.
    Curr Opin Urol. 2023;33:414-420.
    PubMed    
    Abstract available

  220. FENG M, Matoso A, Epstein G, Fong M, et al
    Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://do
    Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  221. KULKARNI GS, Wettstein MS
    SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Oct 4:S0302-2838(23)03138-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  222. KLUMPER N, Eckstein M, Holzel M, Herrmann K, et al
    Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT.
    Eur Urol. 2023;84:514-515.
    PubMed    


  223. ALFRED WITJES J, Max Bruins H, Carrion A, Cathomas R, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
    Eur Urol. 2023 Oct 17:S0302-2838(23)03073-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  224. SEISEN T, Roupret M, Trinh QD, Bellmunt J, et al
    Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J
    Eur Urol. 2023 Oct 19:S0302-2838(23)03163-9. doi: 10.1016/j.eururo.2023.
    PubMed    


  225. SWINTON M, Hoskin P, Choudhury A
    Reply to Thomas Seisen, Morgan Roupret, Quoc-Dien Trinh, and Joaquim Bellmunt's Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alterna
    Eur Urol. 2023 Oct 19:S0302-2838(23)03162-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  226. MEEKS JJ, Black PC, Galsky M, Grivas P, et al
    Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
    Eur Urol. 2023;84:473-483.
    PubMed    
    Abstract available

  227. MARTINI A, Falagario UG, Russo A, Mertens LS, et al
    Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.
    Eur Urol. 2023;84:484-490.
    PubMed    
    Abstract available

  228. WANG Z, Li L, Chu C, Wei X, et al
    CUDC?101 is a potential target inhibitor for the EGFR?overexpression bladder cancer cells.
    Int J Oncol. 2023;63:131.
    PubMed    
    Abstract available

  229. KIKUCHI E, Hayakawa N
    Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
    Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
    PubMed    


  230. FUKUSHIMA H
    Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
    PubMed    


  231. SHIGETA K
    Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
    Int J Urol. 2023;30:859.
    PubMed    


  232. KU JH, Lee LS, Lin TP, Kikuchi E, et al
    Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
    PubMed    
    Abstract available

  233. TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
    Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
    Int J Urol. 2023;30:936-938.
    PubMed    


  234. SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
    Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
    Int J Urol. 2023;30:853-858.
    PubMed    
    Abstract available

  235. XIAOQIN Z, Zhouqi L, Huan P, Xinyi F, et al
    Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.
    Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
    PubMed    
    Abstract available

  236. KAYAR R, Bastug Y, Tokuc E, Topaktas R, et al
    Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
    PubMed    
    Abstract available

  237. GERCEK O, Keles I, Saritas TB, Koyuncu B, et al
    Effect of obturator nerve block during transurethral resection of bladder tumors on the disease recurrence, progression and surgery outcomes.
    Int Urol Nephrol. 2023;55:2765-2772.
    PubMed    
    Abstract available

  238. GERCEK O, Ulusoy K, Yazar VM, Topal K, et al
    Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer.
    Int Urol Nephrol. 2023 Oct 17. doi: 10.1007/s11255-023-03829.
    PubMed    
    Abstract available

  239. WEI C, Deng C, Dong R, Hou Y, et al
    Multi-omics analysis reveals critical metabolic regulators in bladder cancer.
    Int Urol Nephrol. 2023 Oct 26. doi: 10.1007/s11255-023-03841.
    PubMed    
    Abstract available

  240. PAZIR Y, Esmeray A, Caglar U, Erbin A, et al
    Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
    Int Urol Nephrol. 2023 Oct 25. doi: 10.1007/s11255-023-03849.
    PubMed    
    Abstract available

  241. KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
    Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
    J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
    PubMed    
    Abstract available

  242. PRASAD SM
    Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
    PubMed    


  243. MURTHY PB, Sexton WJ
    Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
    PubMed    


  244. BREE KK, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
    PubMed    


  245. BREE K, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
    PubMed    


  246. GABRIEL PE, Lambert T, Dumont C, Gauthier H, et al
    [Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function].
    Prog Urol. 2023;33.
    PubMed    
    Abstract available

  247. HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
    Acute Kidney Injury within 90 days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Sep 22:S0090-4295(23)00807-5. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  248. VEJLGAARD M, Maibom SL, Joensen UN, Moser C, et al
    Microbial trends in infection-related readmissions following radical cystectomy for bladder cancer.
    Urology. 2023 Sep 22:S0090-4295(23)00805-1. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  249. MAJDALANY SE, Yaguchi G, Arora S, Ray C, et al
    Genital Sparing Robot-Assisted Radical Cystectomy with Intracorporeal Neobladder & Paravaginal Repair.
    Urology. 2023;179:202-203.
    PubMed    
    Abstract available

  250. HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
    Reply by Authors: Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Oct 21:S0090-4295(23)00810-5. doi: 10.1016/j.urology.2023.
    PubMed    


  251. GRECO F, Domanico L, Lembo F
    Editorial Comment to Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Oct 21:S0090-4295(23)00809-9. doi: 10.1016/j.urology.2023.
    PubMed    


  252. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    PubMed    
    Abstract available

  253. ALT M, Stecca C, Lin Y, Kazeem G, et al
    Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
    BMC Cancer. 2023;23:919.
    PubMed    
    Abstract available

  254. HE Q, Wu S, Zhou Y, Liu Y, et al
    Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
    BMC Cancer. 2023;23:965.
    PubMed    
    Abstract available

  255. ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
    MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
    BMC Cancer. 2023;23:956.
    PubMed    
    Abstract available

  256. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
    Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
    BMC Cancer. 2023;23:940.
    PubMed    
    Abstract available

  257. LUO L, Xie Q, Wu Y, Li P, et al
    Circular RNA CCT3 is a unique molecular marker in bladder cancer.
    BMC Cancer. 2023;23:977.
    PubMed    
    Abstract available

  258. CHEN JX, Huang WT, Zhang QY, Deng CE, et al
    The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:1018.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;